Related Experiment Video
Updated: May 1, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
[Serum argininosuccinate synthetase (ASS) in patients with chronic hepatitis C treated with interferon]
1Second Department of Internal Medicine, Faculty of Medicine, Kagoshima University.
Abstract:
Serum ASS and serum GPT levels were determined in 16 patients with chronic hepatitis C treated with interferon. In all the patients, the serum ASS level decreased earlier than the serum GPT level, and this tendency was remarkable in patients who excellently responded to the treatment. Furthermore, the serum ASS level was fluctuated when the serum GPT levels being continuously flat in the course of the treatment, probably because of the shorter half life of ASS in the serum. In conclusion, the serum ASS level may catch the effect of interferon on inflammation in the liver more sensitively than the GPT.
More Related Videos
06:28Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
Published on: October 1, 2015
11:36Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Hepatitis
Inhibitors of Viral Protein Synthesis